The Calypso system and the anchored beacon transponder are designed to detect tumor movement to aid in the delivery of lung stereotactic body radiotherapy with more precision, the Palo Alto, Calif.-based company said.
The anchored beacon transponders are designed to be implanted in small airways within or near the tumor target and emit non-ionizing electromagnetic signals which are tracked in real time to keep the treatment beam on target, Varian said.
Varian touted the Calypso as the only device on the market which delivers real-time, continuous 3D tumor position information.
“The 510(k) clearance of the Anchored Beacon transponder expands the application of the Calypso system platform. Using the Calypso system and Anchored Beacon transponder, clinicians can deliver dose to lung tumors with increased confidence and accuracy,” Varian global portfolio solutions VP Ed Vertatschitsch said in a press release.
Earlier this month, Varian said it launched an FDA-cleared version of its Velocity cancer imaging software, including a new Rapidsphere module.
This year’s DeviceTalks Minnesota features four tracks packed with expertly curated content created by the industry for the industry.
ECO-SYSTEM TRACK: focuses on issues impacting medtech companies across Minnesota and beyond. TECHNOLOGY TRACK: drills down on the hottest new tech that is changing medtech. REGULATORY 201 and CLINCAL 201 TRACKS: Hosted by Medical Alley and focuses on the most important trends in regulatory and clinical development.
Take a look at our full agenda.
Use the code "TRACKS" to save 15% on the cost of registration.